Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Invested Capital (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Invested Capital for 7 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 62.54% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 62.54% decrease, with the full-year FY2024 number at $8.0 million, up 1835.28% from a year prior.
  • Invested Capital was $2.9 million for Q3 2025 at Vivos Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $37.7 million in Q2 2021 to a low of $46000.0 in Q3 2023.
  • A 5-year average of $11.0 million and a median of $7.0 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: crashed 99.53% in 2023, then soared 16563.04% in 2024.
  • Vivos Therapeutics' Invested Capital stood at $26.8 million in 2021, then tumbled by 82.09% to $4.8 million in 2022, then crashed by 91.44% to $411000.0 in 2023, then skyrocketed by 1835.28% to $8.0 million in 2024, then plummeted by 63.9% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Invested Capital are $2.9 million (Q3 2025), $4.7 million (Q2 2025), and $4.4 million (Q1 2025).